5 Fastest Growing European Stocks to Invest In

2. Bicycle Therapeutics plc (NASDAQ:BCYC)

On March 18, 2026, RBC Capital lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $7 from $11 and maintained a Sector Perform rating, citing the company’s pivot away from zelenectide as a near-term setback that reduces visibility toward commercialization, though restructuring efforts could generate meaningful cost savings and support a longer-term reset.

On the same day, Oppenheimer analyst Jay Olson lowered the price target on Bicycle Therapeutics plc (NASDAQ:BCYC) to $36 from $44 and maintained an Outperform rating, noting the company’s decision to deprioritize zelenectide-pevedotin despite encouraging data, with resources being redirected toward BT5528 and next-generation programs, including its radio-conjugates portfolio.

On March 17, 2026, Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q4 EPS of (29c), compared to the (95c) consensus estimate, with revenue of $47.96M versus $7.08M consensus. The company said the increase in revenue was primarily driven by recognition of remaining collaboration revenue following termination notices with partners, including Novartis and Bayer. CEO Kevin Lee said the company completed dose selection in the Duravelo-2 trial but, following regulatory feedback, decided to deprioritize zelenectide for internal development and shift focus toward other pipeline programs, alongside a broader strategic reprioritization that includes a proposed workforce reduction.

Bicycle Therapeutics plc (NASDAQ:BCYC) develops novel therapeutics for diseases with limited treatment options.